CD82 and cancer: KAI1/CD82 expression is downregulated in malignant tumors and is closely associated with malignant progression and metastatic spread and prognosis (including breast, colon, lung, ovarian, nasopharyngeal, liver, and pancreatic cancers) [25,41].